Specialty Pharmacy

With integrated specialty pharmacies enabling health systems to improve patient outcomes and lower total medical costs, every hospital will need a solution to support the growing number of patients on outpatient specialty medications.

While progress is being made to advance the Cures Act, it is essential to ensure pharmacy interoperability given pharmacy’s critical role in health care.

The sBLA is reinforced by results from a randomized phase 3 trial that investigated cemiplimab-rwlc in combination with a physician’s choice of platinum-doublet chemotherapy compared to platinum-doublet chemotherapy alone.

The researchers projected that approximately 14 participants would experience a significant worsening of their walking function, however, only 8 participants had their walking function decline.

Evaluating the need to define and standardize how quality can be measured in pharmacy.

The observed increase in patient age at the time of relapse makes the findings even more impressive because longer survival is typically associated with younger age at the time of relapse.

C-CAR039 showed positive efficacy and safety data in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

There are many opportunities for pharmacists to hone and overcome their personal discomfort with exercising power and to broaden their repertoire of leadership skills.

Most pharmacists see a transition from transactional care to more direct patient care responsibilities.

This high efficacy and low toxicity allow the combination treatment to provide a significant quality-of-life benefit to patients.

National Pharmacist Day is celebrated each year on January 12 and it is a chance to celebrate the incredible work that pharmacists do for their patients.

Inclisiran treats adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease who require additional lowering of low-density lipoprotein cholesterol.

Compensation was a positive, while workload, management, and lack of work/life balance are the top reasons for dissatisfaction.

More aggressive competition and uptake could cause larger cuts, estimated at up to $124.5 billion between 2021 and 2025, according to the results of a RAND corporation analysis.

About 48% of individuals experienced a complete or partial response when treated with pembrolizumab, and about two-thirds also had a response that lasted more than 3 years.

Emicizumab (Hemlibra, Roche) is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with hemophilia A with or without factor VIII inhibitors.

Study results establish LAG-3 inhibition as therapeutically relevant third immune checkpoint pathway

The approval is based on efficacy and safety data from 2 positive phase 3 studies that evaluated a combined study population of 166 individuals, which represented the US population with Cushing syndrome.

Inhibiting the activity of group 3 innate lymphoid cells could serve as a new therapeutic approach for neurologic conditions.

The increasing economic burden of treatment may impact patient outcomes.

The goal of the financial counselor is to identify available funding for patient care in a timely manner, but the sheer number of resources and variables involved results in a long, tedious process.

Members, as well as health plans, pharmacy benefit managers, plan sponsors, and reinsurers want to know how to fund these expensive treatments to ensure positive outcomes.

Chemotherapy-induced nausea and vomiting can impact patients’ treatment outcomes.

Luciano Costa, MD, PhD, of the University of Alabama at Birmingham, discusses the next steps for clinical research assessing daratumumab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma.

More transparent drug pricing could improve patient care.

Luciano Costa, MD, PhD, of the University of Alabama at Birmingham, discusses how the results of the trial assessing daratumumab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma may impact the treatment landscape.

Luciano Costa, MD, PhD, of the University of Alabama at Birmingham, discusses the adverse events experienced by patients with newly diagnosed multiple myeloma who were administered daratumumab, carfilzomib, lenalidomide, and dexamethasone.

Jacob D. Soumerai, MD, of Harvard Medical School and Massachusetts General Hospital, discusses next steps in the research assessing zanubrutinib, obinutuzumab, and venetoclax in the treatment of previously untreated chronic lymphocytic leukemia.